ArticleBMC medical genomics2026
A novel MYO6 variant identified in a Chinese family with autosomal dominant non-syndromic hearing loss.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHereditary hearing loss (HL) is a highly heterogeneous disorder that follows various inheritance patterns. Variants of MYO6 gene in DFNA22 are characterised by progressive post-lingual sensorineural HL of varying severity. PATIENTS AND
methodsFive-generation Chinese family with autosomal dominant non-syndromic hearing loss (ADNSHL) was enrolled in this study. Whole-exome sequencing (WES) was performed on the proband and her father to screen for causal variants in the genome, whereas intrafamilial co-segregation of the candidate variants in family members was verified using Sanger sequencing. Furthermore, protein modelling and stability analyses were performed to assess the potential pathogenicity of the candidate mutations.
resultsA previously unreported heterozygous missense variant (NM_004999.4:c.2063 A > G, p.Gln688Arg) in exon 20 of MYO6 using WES and was found to co-segregated with the disease in this family. Molecular dynamics simulations predict that the glutamic acid-to-arginine change in p.(Gln688Arg) alters the normal function, most likely through the altered intermolecular forces of this amino acid with the three nearby polar residues. The structural changes caused by this mutation could potentially affect the myosin ATPase cycle.
conclusionsWe report a novel likely pathogenic missense (c.2063 A > G) variant within of MYO6 in patients with DFNA22. Our findings expand the variant spectrum of MYO6 and ADNSHL in Chinese individuals, which will facilitate early clinical genetic diagnosis and accurate genetic counselling of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.